Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACT
Molecular targets to facilitate early detection and preventative therapy for women at high risk for breast cancer have not been characterized. Two recently characterized intracellular enzymes --human telomerase reverse transcriptase (hTERT) and the cytochrome P450 isoform 1B1 (CYP1B1), each overexpressed in >90% of invasive breast cancers but rarely found in normal tissue --may fill this gap. Such targets, if found at the earliest time of malignant transformation, may be ideally suited not only for early detection but also cancer prevention by vaccination. A growing clinical experience in advanced cancer patients has underscored the safety and feasibility of vaccination strategies. The universal expression of hTERT and CYP1B1 provide an opportunity for both early detection and cancer vaccination. Objective/Hypothesis: We hypothesize that immunologic responses can be elicited in advanced breast cancer patients using vaccines incorporating hTERT, providing a safety and feasibility platform for ultimately vaccinating women at high risk for breast cancer. Although we have not found ductal lavage a feasible strategy for the detection of tumor antigens, we have made significant progress on vaccination strategies in women with metastatic breast cancer.
A. INTRODUCTION
This grant supports studies to understand the potential of universal tumor antigens for cancer immunotherapy, with a particular focus on the characterization of the human telomerase reverse transcriptase (hTERT) as tumor antigen. Telomerase is expressed by >90% of all human breast cancers but absent in most normal cells. Telomerase function has been directly linked to oncogenesis and its inhibition in telomerase-positive human tumors leads to growth arrest.
Following a series of published in vitro preclinical experiments, we are now testing the hypothesis of telomerase as a tumor rejection antigen in vivo in humans. After our past work in completing the dose escalation portion of the hTERT vaccine trial, as well as enrolling additional patients on the optimal dose level, this year we proceeded with work evaluating intravenous cyclophosphamide prior to hTERT vaccination in an attempt to boost vaccine response by depleting regulatory T cells. Funding has been obtained to continue this work beyond the end of the Department of Defense grant.
B. BODY
Aim 1: Evaluation of molecular markers in ductal lavage fluid from BRCA1 and BRCA2 mutation carriers Increasing data have demonstrated significant limitations regarding ductal lavage, particularly in BRCA1/2 mutation carriers. Data by several groups have demonstrated that fluid yielding ducts are much less common in women following oophorectomy or taking selective estrogen receptor modulations (SERMS), situations which apply to the majority of BRCA1 and BRCA2 mutation carriers. In addition, the cellular yield of non-fluid yielding ducts is significantly lower than in fluid yielding ducts. Finally, ductal lavage has a low sensitivity for the detection of malignancy as examined by ductal lavage prior to mastectomy for known cancers. As the 5majority of our BRCA1/2 carriers have had oophorectomy, it is our opinion that the value of ductal lavage is quite limited and the approach not feasible. Therefore, we examined the value of oophorectomy on mortality in BRCA1/2 mutation carriers. We felt that this was a much better use of DOD resources.
In the primary analysis of this study, which was published in Lancet Oncology, we examined 426 women unaffected with either breast or ovarian cancer at the start of study entry. Study participants who choose to undergo oophorectomy were age-matched to those who did not. At a median follow-up of 2-3 years, PO led to a risk reduction for breast cancer (HR 0.36, 0.20-0.67) and ovarian cancer (HR 0.11, 0.03-0.47) consistent with prior reports. In addition, a reduction in breast cancer specific mortality (HR 0.10, 0.02-0.71), ovarian cancer specific mortality (HR 0.05, 0.01-0.46) and overall mortality (HR 0.24, 0.08-0.71) were also seen. Median follow-up time in this study is short, and the sample size still relatively small. Despite the limitations, these data provide further evidence that PO in BRCA1/2 mutation carriers is of benefit. of such cells at baseline in these patients or in immunological non-responders at any time point). T cells were specific for hTERT peptide and recognized telomerase-positive, HLA-A2+ (but not HLA-A2-negative) carcinoma cells, as shown by IFN-gamma production and cytotoxicity assays. For three patients undergoing tumor biopsy, hTERT-specific CD8+ tumor infiltrating lymphocytes (TIL) were observed by tetramer analysis after, but not before, vaccination, measuring >5% tetramer+ cells among CD8+ T cells. In two patients, TILs were associated with marked tumor necrosis. The most common adverse events were Grade 1-2 injection site reactions and a syndrome of tumor pain or tumor-site pruritis after vaccination.
By a landmark survival analysis, we investigated the association of the induction of hTERTspecific CTL in peripheral blood and survival. For 14 patients who received at least four vaccines, the landmark was defined as the immune response status after the fourth vaccination (median on study day 70, range 55-78 Moreover, we also used tetramer analysis to track responses to the CMV control peptide in the vaccine. We found that by landmark analysis there was no correlation between overall survival and CMV response 1 month after the fourth vaccination.
These results suggest that telomerase vaccination of patients with metastatic breast cancer induces hTERT-specific T cells that may impact overall survival. Interestingly, the primary immune assay used as the endpoint in this survival analysis was tetramer labeling. This year we have treated 5 patients with intravenous cyclophosphamide prior to the administration of hTERT vaccine to assess whether such an intervention might enhance immune response. Preliminary data does not support this hypothesis, although detailed immunological assessments are underway. 
C. Funding
Dr. Domchek is a co-investigator on a RO1 which was funded this year. This grant permits the evaluation of I540 peptide vaccination in combination with anti-CD25 mAb in a further attempt to boost immune response by depleting regulatory T cells. The principle investigator on the grant is Dr. Robert Vonderheide, and the grant number is Ro1 CA111377-01A1. Dr. Domchek will be the principle investigator on the clinical trial which will be part of the grant. In addition, Dr. Domchek is the clinical PI of a project entitled, "Telomerase Immunotherapy in Breast Cancer" submitted as part of a PENN/Fox Chase Cancer Center SPORE application. Dr. Domchek's work in breast cancer genetics has resulted in a Cancer Genetics Network Contract through the National Cancer Institute as the University of Pennsylvania site PI. Finally, Dr. Domchek is the lead clinical investigator on two RO1's led by Dr. Timothy Rebbeck (RO1 CA102776 and RO1 CA083855). The first of these grants is examining the impact of prophylactic surgery on BRCA1/2 mutation carriers, with particular attention to tumor phenotype as well as interaction with hormonal therapy use. The second study is focused on modifier genes in BRCA1/2 mutation carriers.
CONCLUSIONS
Data thus far from our current trial suggest that telomerase peptide vaccination is biologically active and leads to in vivo immune recognition of carcinoma by effector lymphocytes and tumor necrosis. This has great potential for biological therapy of breast cancer and required further exploration. If hTERT expression can be found in women at high risk for breast cancer, this may represent a marker to be used to target candidates for vaccination in the future. 
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